DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta9-tetrahydrocannabinol.

Author(s): Lile JA, Kelly TH, Hays LR

Affiliation(s): Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY 40536-0086, USA. jalile2@email.uky.edu

Publication date & source: 2010-09, Clin Neuropharmacol., 33(5):235-42.

Publication type: Research Support, N.I.H., Extramural

OBJECTIVES: The central effects of Delta-tetrahydrocannabinol (Delta-THC), the primary active constituent of cannabis, are attributed to cannabinoid CB1 receptor activity, although clinical evidence is limited. Drug discrimination has proven useful for examining the neuropharmacology of drugs, as data are concordant with the actions of a drug at the receptor level. The aim of this study was to determine the profile of behavioral and physiological effects of the cannabinoid agonist nabilone in humans trained to discriminate Delta-THC. METHODS: Six cannabis users learned to identify when they received oral Delta-THC (25 mg) or placebo and then received a range of doses of the cannabinoid agonists nabilone (1, 2, 3, and 5 mg) and Delta-THC (5, 10, 15, and 25 mg). The dopamine reuptake inhibitor methylphenidate (5, 10, 20, and 30 mg) was included as a negative control. Subjects completed the Multiple-Choice Procedure, and self-report, task performance, and physiological measures were collected. RESULTS: Nabilone shared discriminative-stimulus effects with the training dose of Delta-THC, produced subject-rated drug effects that were comparable to those of Delta-THC, and increased heart rate. Methylphenidate did not engender Delta-THC-like discriminative-stimulus effects. CONCLUSIONS: These data demonstrate that the interoceptive effects of nabilone are similar to Delta-THC in cannabis users. The overlap in their behavioral effects is likely due to their shared mechanism as CB1 receptor agonists. Given the relative success of agonist replacement therapy to manage opioid, tobacco, and stimulant dependence, these results also support the evaluation of nabilone as a potential medication for cannabis-use disorders.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017